Rituximab in early systemic sclerosis

OBJECTIVES: (1) Hypothesis testing of the potency of rituximab (RTX) in preventing fibrotic complications and (2) assessing acceptability and feasibility of RTX in early systemic sclerosis (SSc). METHODS: A small, 24-month, randomised, double-blind, placebo-controlled, single-centre trial in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Boonstra, Maaike, Meijs, Jessica, Dorjée, Annemarie L, Marsan, Nina Ajmone, Schouffoer, Anne, Ninaber, Maarten K, Quint, Koen D, Bonte-Mineur, Femke, Huizinga, Tom W J, Scherer, Hans U, de Vries-Bouwstra, Jeska K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574444/
https://www.ncbi.nlm.nih.gov/pubmed/28879049
http://dx.doi.org/10.1136/rmdopen-2016-000384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574444/
https://www.ncbi.nlm.nih.gov/pubmed/28879049
http://dx.doi.org/10.1136/rmdopen-2016-000384

Ejemplares similares